Description
Super Human Blend is a pre-mixed research formulation combining multiple compounds from the areas of growth, repair and performance in one vial. Typical configurations include components of the GH secretagogue family (CJC, ipamorelin), repair peptides (BPC-157, TB-500) and partially additional compounds for broader coverage. The exact composition varies by vendor and research batch.
In research context, Super Human Blend addresses multiple complementary pathways simultaneously: GH axis (via secretagogues), tissue repair (via BPC-157), stem cell mobilization (via TB-500) and depending on configuration additional axes. This multi-pathway coverage makes the blend an efficient tool for comprehensive performance research setups.
The practical advantage of a pre-mixed blend lies in reduced operational complexity: one vial, one reconstitution step, one application routine. In multi-week research setups, this reduces the error rate and simplifies study logistics.
Compared to mechanistically focused mono-compounds, multi-component blends provide broader coverage but reduced mechanism clarity. For isolated pathway studies, solo compounds are the better choice; for comprehensive research overviews, blends are efficient.
Super Human Blend is primarily established in recovery- and performance-oriented research setups. The exact component configuration is vendor-specific and should be verified with the supplier before research application.
Super Human Blend is available in 16mg vials as 10-vial packs.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Super Human Blend combines several already well tolerated peptides in one vial and is considered mild per study reports, but the multi-component character brings its own classification points.
Observed in research and reports:
- Injection site: mild redness, pressure or transient irritation at the injection site is the most common observation, as with the individual components.
- Combined profile: because the blend unites components such as GH secretagogues, BPC-157 and TB-500, their individually mild effect profiles add up. The individual constituents are considered well tolerated, but the behavior of the exact combination is less studied in isolation.
- Vendor-dependent composition: the exact component configuration varies by vendor and batch. The safety profile is therefore not identical for every batch and should be verified before research application.
- Limited data on the mixture: robust studies on exactly this pre-mixed formulation are absent. The classification rests on the data of the individual compounds.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Combination peptide protocols in research - Peptides 2014: Research context of combined protocols.
- GH secretagogues and tissue repair - European Journal of Endocrinology 2009: Pathway synergies.
- BPC-157 and growth peptide combinations - Pharmaceuticals 2025: Combined repair research.